var data={"title":"Amifostine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amifostine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5607?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">see &quot;Amifostine: Drug information&quot;</a> and <a href=\"topic.htm?path=amifostine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amifostine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132861\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ethyol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132862\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ethyol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044992\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Cisplatin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cytoprotective Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044985\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">see &quot;Amifostine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual protocols.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cytoprotective agent against cisplatin or high-dose alkylating agents:</b> Limited data available: Efficacy results variable:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Gastrointestinal and hematologic toxicity reduction:</i> Infants, Children, and Adolescents: IV: 740 mg/m<sup>2</sup>/dose once daily prior to cytotoxic chemotherapy. In a study of patients (n=11, age range: 2.5 months to 17 years) receiving the same combination chemotherapy at the same doses (including cisplatin or high-dose alkylating agent) with or without amifostine, patients who received amifostine had significantly reduced incidences of mucositis and gastrointestinal toxicities and a significantly reduced requirement for erythrocyte transfusions. However, there was no difference in the number of platelet transfusions required (Ceting&uuml;l 2009). In another study in osteosarcoma patients treated with cisplatin or carboplatin as part of combination chemotherapy, there was a reduction in neutrophil and leukocyte toxicity in patients who received amifostine (n=17) compared to those who did not (n=19); however, amifostine did not protect against platelet effects (Petrilli 2002). Other studies have not shown protection against myelosuppression (Adamson 1995; Bernstein 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Nephrotoxicity reduction:</i> Children and Adolescents: IV: 740 mg/m<sup>2</sup>/dose given immediately prior to cisplatin. In a small study of intracavitary cisplatin therapy for solid tumors, three patients (ages: 2 to 6 years) received amifostine. Of these patients, only one experienced persistent renal dysfunction (Katzenstein 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Reduction of platinum-induced hearing loss:</i> Children and Adolescents 3 to 20 years: IV: 600 mg/m<sup>2</sup>/dose given immediately prior to and 3 hours into cisplatin administration has been shown to reduce cisplatin-induced hearing loss in patients with average-risk medulloblastoma. Amifostine did not protect against hearing loss in patients with high-risk medulloblastoma (Fouladi 2008; Gurney 2014). Other studies using a single dose of 740 mg/m<sup>2</sup> or 825 mg/m<sup>2</sup> immediately prior to cisplatin did not prevent ototoxicity (Katzenstein 2009; Marina 2005; Petrilli 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Xerostomia, moderate to severe from radiation of the head and neck, reduction:</b> Limited data available: Children &ge;7 years and Adolescents: SubQ: 200 mg once daily given 30 minutes prior to standard fraction radiation therapy. Dosing based on a small pilot study in pediatric patients who received subcutaneous amifostine (n=5, age range: 7 to 15 years) for a total of 129 injections. No grade 3 or 4 mucosal or skin reactions occurred (Anacak 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Antiemetic medication, including dexamethasone 20 mg IV and a serotonin 5-HT<sub>3</sub> receptor antagonist, is recommended prior to and in conjunction with amifostine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cisplatin-induced renal toxicity, reduction:</b> IV: 910 mg/m<sup>2</sup> once daily administered 30 minutes prior to cytotoxic chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The infusion of amifostine should be interrupted if the systolic blood pressure decreases significantly from baseline, as defined below:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Decrease of 20 mm Hg if baseline systolic blood pressure &lt;100</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Decrease of 25 mm Hg if baseline systolic blood pressure 100 to 119</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Decrease of 30 mm Hg if baseline systolic blood pressure 120 to 139</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Decrease of 40 mm Hg if baseline systolic blood pressure 140 to 179</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Decrease of 50 mm Hg if baseline systolic blood pressure &ge;180</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If blood pressure returns to normal within 5 minutes (assisted by fluid administration and postural management) and the patient is asymptomatic, the infusion may be restarted so that the full dose of amifostine may be administered. If the full dose of amifostine cannot be administered, the dose of amifostine for subsequent cycles should be 740 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Xerostomia, moderate to severe from radiation of the head and neck, reduction:</b> IV: 200 mg/m<sup>2</sup> once daily starting 15 to 30 minutes prior to standard fraction radiation therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dermatologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Rash involving lips or mucosa (of unknown etiology outside of radiation port) and for bullous, edematous or erythematous lesions on hands, feet, or trunk: Withhold treatment and obtain dermatologic consultation; reinitiate only after careful evaluation.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe/serious cutaneous reaction associated with fever (or other constitutional symptoms) or severe acute allergic reaction: Discontinue treatment permanently.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132843\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ethyol: 500 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132828\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044996\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Administer amifostine doses &ge;600 mg/m<sup>2</sup> as an IV intermittent infusion over 15 minutes since the 15-minute infusion is better tolerated than a more prolonged infusion. Administer 200 mg/m<sup>2</sup> dose as a 3-minute infusion. Patients should be kept in supine position during infusion and amifostine should be interrupted if the blood pressure decreases significantly from baseline or if the patient develops symptoms related to decreased cerebral or cardiovascular perfusion. Patients experiencing decreased blood pressure should receive a rapid infusion of NS and be kept supine or placed in the Trendelenburg position. Amifostine can be restarted if the blood pressure returns to the baseline level. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132856\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Reconstituted solutions (500 mg/10 mL) and solutions diluted in NS (in polyvinyl chloride [PVC] bags) for infusion are chemically stable for up to 5 hours at room temperature (~25&deg;C [~77&deg;F]) or up to 24 hours under refrigeration (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044995\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer (FDA approved in adults); reduction of moderate to severe xerostomia from radiation treatment of the head and neck where the radiation port includes a substantial portion of the parotid glands (FDA approved in adults); has also been used as a cytoprotective agent to selectively protect normal tissues against toxicity due to cytotoxic chemotherapy. <b>Note: </b>The clinical data do not suggest the efficacy of cisplatin-based chemotherapy or radiation therapy for the approved indications is altered by amifostine. Data on the effects of amifostine on the efficacy of chemotherapy or radiotherapy in other settings is limited. Do not administer amifostine in other settings where chemotherapy can produce a significant survival benefit or cure, or in patients receiving definitive radiotherapy, unless within the context of a clinical study.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132900\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ethyol may be confused with ethanol</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132897\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia, chest pain, extrasystoles, flushing, hypotension (more common in ovarian cancer; generally transient), ischemic heart disease, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, dizziness, drowsiness, malaise, sensation of cold</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema multiforme, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypocalcemia (head and neck cancer; clinically significant)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, hiccups, nausea and vomiting (more common in ovarian cancer), severe nausea and vomiting (more common in ovarian cancer)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction (includes bruising at injection site, erythema at injection site, inflammation at injection site, injection site pruritus, pain at injection site, rash at injection site, swelling at injection site, urticaria at injection site)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, diplopia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Apnea, dyspnea, hypoxia, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, atrial fibrillation, atrial flutter, cardiac arrhythmia, DRESS syndrome, hypersensitivity reaction (includes chest discomfort, laryngeal edema, pruritus, rigors, urticaria), myocardial infarction, renal failure, seizure, Stevens-Johnson syndrome, supraventricular tachycardia, syncope, toxic epidermal necrolysis, transient hypertension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132849\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amifostine, aminothiol compounds, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132832\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Serious cutaneous reactions (some fatal), including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, toxicoderma, exfoliative dermatitis, and drug reaction with biopsy-proven eosinophilia and system symptoms (DRESS) have been reported with amifostine. May be delayed, developing up to weeks after treatment initiation. Cutaneous reactions have been reported more frequently when used as a radioprotectant. Evaluate for dermatologic reactions prior to each dose, during therapy and after treatment discontinuation. Discontinue treatment for severe/serious cutaneous reactions or mucosal lesions that appear outside of the radiation port and for bullous, edematous, or erythematous lesions on the palms or soles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Rare hypersensitivity reactions, including anaphylaxis and allergic reaction, have been reported. Discontinue if severe acute allergic reaction occurs; do not rechallenge. Medications for the treatment of hypersensitivity reactions should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypocalcemia: Reports of clinically-relevant hypocalcemia are rare, but serum calcium levels should be monitored in patients at risk of hypocalcemia, such as those with nephrotic syndrome, or patients receiving multiple amifostine doses. May require calcium supplementation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Hypotension may occur during or shortly after infusion. Short term (reversible) syncope (loss of consciousness) has been rarely reported. Patients who are hypotensive or dehydrated should not receive amifostine. Adequately hydrate prior to treatment and keep in a supine position during the infusion. Monitor blood pressure every 5 minutes during the infusion. If hypotension requiring interruption of therapy occurs, patients should be placed in the Trendelenburg position and given an infusion of normal saline using a separate IV line; subsequent infusions may require a dose reduction. Infusions &gt;15 minutes are associated with a higher incidence of adverse effects. Interrupt antihypertensive therapy for 24 hours before treatment; patients who cannot safely stop their antihypertensives 24 hours before should not receive amifostine.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nausea/vomiting: Amifostine doses &gt;300 mg/m<sup>2</sup> are associated with a moderate emetic potential (Dupuis 2011). The incidence of nausea and vomiting is higher in patients receiving amifostine compared to chemotherapy alone. Antiemetic medications, including dexamethasone 20 mg IV and a serotonin 5-HT<sub>3</sub> receptor antagonist, should be administered prior to and in conjunction with amifostine. Use with caution in patients for whom the adverse effects of nausea/vomiting may have serious adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or whom the adverse effects of hypotension may have serious adverse events.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular disease: Use with caution in patients with cerebrovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: According to the manufacturer, amifostine should not be used (in patients receiving chemotherapy for malignancies other than ovarian cancer) where chemotherapy is expected to provide significant survival benefit or in patients receiving definitive radiotherapy, unless within the context of a clinical trial. The American Society of Clinical Oncology (ASCO) has published guidelines for the use of protectants for chemotherapy and radiation (Hensley 2009). According to the ASCO guidelines, amifostine may be considered for prevention of nephrotoxicity in patients receiving cisplatin-based therapy. While amifostine may be considered to reduce the incidence of grade 3 or 4 neutropenia associated with chemotherapy, the guidelines suggest that alternative strategies (eg, growth factors) may be utilized in this situation. The guidelines recommend against the use of amifostine to reduce the incidence of thrombocytopenia associated with chemotherapy or radiation therapy. Data is insufficient to recommend amifostine for prevention of neurotoxicity or ototoxicity associated with platinum-based chemotherapy, for prevention of neurotoxicity associated with paclitaxel, for prevention of radiation therapy-induced mucositis associated with head and neck cancer, or for prevention of esophagitis due to chemotherapy in patients with non-small cell lung cancer. Additionally, amifostine may be considered to decrease the incidence of acute and late xerostomia in patients undergoing radiation therapy alone (for head and neck cancer); however, the guidelines do not support the use of amifostine in patients with head and neck cancer receiving concurrent platinum-based chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298731\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132837\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13399&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2930085\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1044991\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Baseline blood pressure followed by a blood pressure reading every 5 minutes during the infusion and after administration if clinically indicated; monitor electrolytes, urinalysis, serum calcium, serum magnesium; monitor I &amp; O; evaluate for cutaneous reactions prior to each dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132831\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Amifostine is a prodrug that is dephosphorylated by alkaline phosphatase in tissues to a pharmacologically-active free thiol metabolite. The free thiol is available to bind to, and detoxify, reactive metabolites of cisplatin; and can also act as a scavenger of free radicals that may be generated (by cisplatin or radiation therapy) in tissues.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132848\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic dephosphorylation to two metabolites (active-free thiol and disulfide)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Children: 9.3 minutes (Fouladi 2001); Adults: ~8 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (minimal; as amifostine and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322980\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ethyol Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (1): $1,275.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F132852\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Amifos (PK);</li>\n      <li>Amiphos (IN);</li>\n      <li>Erifostine (AR);</li>\n      <li>Ethyol (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CO, CR, CY, CZ, DE, DK, DO, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KR, LU, MX, NI, NL, NZ, PA, PE, PH, PL, PT, QA, SE, SV, TR, TW, UY, VE);</li>\n      <li>Tian Di Da (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adamson PC, Balis FM, Belasco JE, et al, &ldquo;A Phase I Trial of Amifostine (WR-2721) and Melphalan in Children With Refractory Cancer,&rdquo; <i>Cancer Res</i>, 1995, 55(18): 4069-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/7664282/pubmed\" target=\"_blank\" id=\"7664282\">7664282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anacak Y, Kamer S, Haydaroglu A. Daily subcutaneous amifostine administration during irradiation of pediatric head and neck cancers. <i>Pediatr Blood Cancer </i>. 2007;48:579-581.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/16395679/pubmed\" target=\"_blank\" id=\"16395679\">16395679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernstein MJ, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: pediatric oncology group/children&rsquo;s cancer group phase II study 9457 &ndash; a report from the children&rsquo;s oncology group. <i>Journal of Clinical Oncology</i>. 2006;24(1):152-159.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/16382125/pubmed\" target=\"_blank\" id=\"16382125\">16382125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ceting&uuml;l N, Midyat L, Kantar M, Demira&#287; B, Aksoylar S, Kansoy S. Cytoprotective effects of amifostine in the treatment of childhood malignancies. <i>Pediatr Blood Cancer</i>. 2009;52:829-833.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/19214974/pubmed\" target=\"_blank\" id=\"19214974\">19214974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ethyol (amifostine) [prescribing information]. Bedford, OH: Ben Venue, Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fouladi M, Chinagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. <i>J Clin Oncol</i>. 2008;26(22):3749-3755.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/18669462/pubmed\" target=\"_blank\" id=\"18669462\">18669462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fouladi M, Stempak D, Gammon J, et al, &ldquo;Phase I Trial of a Twice-Daily Regimen of Amifostine With Ifosfamide, Carboplatin, and Etoposide Chemotherapy in Children With Refractory Carcinoma,&rdquo; <i>Cancer</i>, 2001, 92(4):914-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/11550166 /pubmed\" target=\"_blank\" id=\"11550166 \">11550166 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gurney JG, Bass JK, Onar-Thomas A, et al. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma. <i>Neuro Oncol</i>. 2014;16(6):848-855.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/24414535/pubmed\" target=\"_blank\" id=\"24414535\">24414535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo; <i>J Clin Oncol</i>, 2009, 27(1): 127-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/19018081/pubmed\" target=\"_blank\" id=\"19018081\">19018081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katzenstein HM, Chang KW, Krailo M, et.al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. A report of the intergroup hepatoblastoma study P9645 as a part of the children&rsquo;s oncology group. <i>Cancer</i>. 2009;115(24):5828-5835.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/19813275/pubmed\" target=\"_blank\" id=\"19813275\">19813275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katzenstein HM, Petricca S, Ricketts R, et al. Intracavitary cisplatin therapy for pediatric malignancies. <i>Pediatr Blood Cancer </i>. 2010;55:452-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/20658616/pubmed\" target=\"_blank\" id=\"20658616\">20658616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect agains the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors. <i>Cancer</i>. 2005;104:841-847.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/15999362/pubmed\" target=\"_blank\" id=\"15999362\">15999362</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescemts. <i>Journal of Pediatric Hematology/Oncology</i>. 2002;24(3):188-191.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/11990304/pubmed\" target=\"_blank\" id=\"11990304\">11990304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw LM, Bonner H, and Lieberman R, &ldquo;Pharmacokinetic Profile of Amifostine,&rdquo; <i>Semin Oncol</i>, 1996, 23(4 Suppl 8):18-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amifostine-pediatric-drug-information/abstract-text/8783662/pubmed\" target=\"_blank\" id=\"8783662\">8783662</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13399 Version 102.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F132861\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F132862\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1044992\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1044985\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F132843\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F132828\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1044996\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F132856\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1044995\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F132900\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F132897\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F132849\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F132832\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298731\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F132837\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2930085\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1044991\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F132831\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F132848\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322980\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F132852\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13399|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amifostine-drug-information\" class=\"drug drug_general\">Amifostine: Drug information</a></li><li><a href=\"topic.htm?path=amifostine-patient-drug-information\" class=\"drug drug_patient\">Amifostine: Patient drug information</a></li></ul></div></div>","javascript":null}